161 related articles for article (PubMed ID: 25260789)
1. Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case-control study.
Lim YP; Lin CL; Hung DZ; Lin YN; Kao CH
Eur J Clin Microbiol Infect Dis; 2015 Mar; 34(3):479-85. PubMed ID: 25260789
[TBL] [Abstract][Full Text] [Related]
2. Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.
Lee YR; Tien NI; Lin CL; Shen HY; Bau DT; Lim YP
In Vivo; 2018; 32(1):47-54. PubMed ID: 29275298
[TBL] [Abstract][Full Text] [Related]
3. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Fresard I; Bridevaux PO; Rochat T; Janssens JP
Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
[TBL] [Abstract][Full Text] [Related]
4. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
Arguello Perez E; Seo SK; Schneider WJ; Eisenstein C; Brown AE
Clin Infect Dis; 2017 Nov; 65(12):2105-2111. PubMed ID: 29020308
[TBL] [Abstract][Full Text] [Related]
5. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.
Jahng AW; Tran T; Bui L; Joyner JL
Transplantation; 2007 Jun; 83(12):1557-62. PubMed ID: 17589337
[TBL] [Abstract][Full Text] [Related]
6. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
Almeida D; Nuermberger E; Tasneen R; Rosenthal I; Tyagi S; Williams K; Peloquin C; Grosset J
Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
[TBL] [Abstract][Full Text] [Related]
8. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
Lin HS; Cheng CW; Lin MS; Chou YL; Chang PJ; Lin JC; Ye JJ
Clin Interv Aging; 2016; 11():299-306. PubMed ID: 27042029
[TBL] [Abstract][Full Text] [Related]
9. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
Long MW; Snider DE; Farer LS
Am Rev Respir Dis; 1979 Jun; 119(6):879-94. PubMed ID: 110184
[TBL] [Abstract][Full Text] [Related]
10. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
Bray MG; Poulain C; Dougados M; Gossec L
Joint Bone Spine; 2010 Mar; 77(2):135-41. PubMed ID: 20097592
[TBL] [Abstract][Full Text] [Related]
11. Treatment of extrapulmonary tuberculosis.
Dutt AK; Stead WW
Semin Respir Infect; 1989 Sep; 4(3):225-31. PubMed ID: 2688005
[TBL] [Abstract][Full Text] [Related]
12. Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis?
Denkinger CM; Pai M; Dowdy DW
PLoS One; 2014; 9(1):e84197. PubMed ID: 24404155
[TBL] [Abstract][Full Text] [Related]
13. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
14. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
[TBL] [Abstract][Full Text] [Related]
15. Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using the Quantamatrix Multiplexed Assay Platform System.
Wang HY; Uh Y; Kim S; Cho E; Lee JS; Lee H
Ann Lab Med; 2018 Nov; 38(6):569-577. PubMed ID: 30027701
[TBL] [Abstract][Full Text] [Related]
16. Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India.
Ranjalkar J; Mathew SK; Verghese VP; Bose A; Rose W; Gupta D; Fleming DH; Mathew BS
Int J Antimicrob Agents; 2018 May; 51(5):663-669. PubMed ID: 29241821
[TBL] [Abstract][Full Text] [Related]
17. Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation.
Ichai P; Saliba F; Antoun F; Azoulay D; Sebagh M; Antonini TM; Escaut L; Delvart V; Castaing D; Samuel D
Liver Transpl; 2010 Oct; 16(10):1136-46. PubMed ID: 20879012
[TBL] [Abstract][Full Text] [Related]
18. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
[TBL] [Abstract][Full Text] [Related]
19. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
20. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
